---
title: 'Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma:
  drug targets and potential pharmacotherapies'
date: '2023-10-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37897190/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231029180831&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: H3 K27-altered diffuse midline glioma (DMG) is the most
  common malignant brainstem tumor in the pediatric population. Despite enormous preclinical
  and clinical efforts, the prognosis remains dismal, with fewer than 10% of patients
  surviving for two years after diagnosis. Fractionated radiation remains the only
  standard treatment options for DMG. Developing novel treatments and therapeutic
  delivery methods is critical to improving outcomes in this devastating ...'
disable_comments: true
---
INTRODUCTION: H3 K27-altered diffuse midline glioma (DMG) is the most common malignant brainstem tumor in the pediatric population. Despite enormous preclinical and clinical efforts, the prognosis remains dismal, with fewer than 10% of patients surviving for two years after diagnosis. Fractionated radiation remains the only standard treatment options for DMG. Developing novel treatments and therapeutic delivery methods is critical to improving outcomes in this devastating ...